Mediator measurements after daily instillation of allergen: Increased IL-5 and decreased IFN-gamma

Allergy and Asthma Proceedings

Volumn 29, Issue 2, 2008, Pages 146-151

  McDermott, Robert A ^a,b   Nelson, Harold S ^b   Dreskin, Stephen C ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c NONE   (United States)

Author keywords

Allergen challenge; Cytokines; Eosinophilic cationic protein; Inflammation; Mediators; Nasal challenge; Priming effect; Rhinitis

Indexed keywords

ALLERGEN; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HAY FEVER; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ADULT; ALLERGENS; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; INTERLEUKIN-5; MALE; MIDDLE AGED; RHINITIS, ALLERGIC, SEASONAL;

EID: 43149102277     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3094     Document Type: Article

References (16)

1. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 21:7-13, 2000.
2. Schoenwetter WF. Allergic rhinitis: Epidemiology and natural history. Allergy Asthma Proc 21:1-6, 2000.
3. Meltzer, EO, TB Casale, RA Nathan, and AK Thompson. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 83:311-317, 1999.
4. Sim, TC, JA Grant, KA Hilsmeier, et al. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am J Respir Crit Care Med 149:339-344, 1994.
5. Sim TC, Reece LM, Hilsmeier KA, et al. Secretion of chemokines and other cytokines in allergen-induced nasal responses: Inhibition by topical steroid treatment. Am J Respir Crit Care Med 152:927-933, 1995.
6. Dreskin S, Dale S, Foster S, et al. Measurement of mRNA for IL-5 in scrapings of nasal epithelium from patients with allergic rhinitis undergoing nasal allergen challenge. J Immunol Methods 268:189-195, 2002.
7. Andersson M, Svensson C, Persson C, et al. Dose-dependent effects of budesonide aqueous nasal spray on symptoms in a daily nasal allergen challenge model. Ann Allergy Asthma Immunol 85:279-283, 2000.
8. Connell JT. Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis. J Allergy 43:33-44, 1969.
9. Connell JT. Quantitative intranasal pollen challenge. II. Effect of daily pollen challenge, environmental pollen exposure, and placebo challenge on the nasal membrane. J Allergy 41:123-139, 1968.
10. Pipkorn U, Proud D, Lichtenstein LM, et al. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 80:957-961, 1987.
11. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 97:1356-1365, 1996.
12. Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy [see Comments]. J Allergy Clin Immunol 99:254-260, 1997.
13. Jacobi HH, Skov PS, Kampen GT, et al. Histamine and tryptase in nasal lavage fluid following challenge with methacholine and allergen. Clin Exp Allergy 28:83-91, 1998.
14. Linden M, Svensson C, Andersson M, et al. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Allergy 54:212-219, 1999.
15. Kramer MF, Ostertag P, Pfrogner E, and Rasp G. Nasal IL-16 and MIP-1 alpha in late-phase allergic response. Allergy Asthma Proc 22:127-132, 2001.
16. Naclerio RM, Meier HL, Kagey A-Sobotka, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 128:597-602, 1983.